SCHEMBL4987306

SCHEMBL4987306

COCc1cccc(Cl)c1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HSD17B10 Q99714 1/20 0.49
NR4A2 P43354 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
FEN1 P39748 1/20 0.43
GAA P10253 1/20 0.42
PBRM1 Q86U86 1/20 0.41
KMT2A Q03164 2/20 0.41
DPP4 P27487 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27697961 0.85 ALDH1A1 (0.45) ALDH1A1KDM4EHSD17B10CA12CA1
SCHEMBL4996201 0.84 LMNA (0.50) ALDH1A1NR4A2NPC1RAB9ACA12
SCHEMBL4504893 0.83 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10FEN1GAA
SCHEMBL27853749 0.81 ALDH1A1 (0.50) ALDH1A1KDM4EHSD17B10NR4A2NPC1
SCHEMBL3006057 0.79 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10NR4A2NPC1
SCHEMBL8477197 0.79 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10NR4A2NPC1
SCHEMBL22090410 0.79 CA12 (0.44) ALDH1A1CA12CA1CA2CA7
SCHEMBL5163919 0.79 BID (0.51) KDM4EHSD17B10PPARA
SCHEMBL2336044 0.78 AKR1B1 (0.62) ALDH1A1FEN1
SCHEMBL1815662 0.78 PNMT (0.55) ALDH1A1NR4A2NPC1RAB9AFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S ASTEX THERAPEUTICS LIMITED (UK) 2008-12-11 US disclosed
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S ASTEX THERAPEUTICS LIMITED (UK) 2008-12-11 US disclosed
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S ASTEX THERAPEUTICS LIMITED (UK) 2008-12-11 US disclosed
US-20080194562-A1 Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's ASTEX THERAPEUTICS LIMITED (GB) 2008-08-14 US disclosed
US-20080194562-A1 Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's ASTEX THERAPEUTICS LIMITED (GB) 2008-08-14 US disclosed
US-20080194562-A1 Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's ASTEX THERAPEUTICS LIMITED (GB) 2008-08-14 US disclosed
CN-101146806-A Pyrazole derivatives for the inhibition of CDK and GSK ASTEX THERAPEUTICS LTD (GB) 2008-03-19 CN disclosed
CN-101146795-A Pyrazole derivatives for the inhibition of CDK and GSK ASTEX THERAPEUTICS LTD (GB) 2008-03-19 CN disclosed
EP-1853600-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S Astex Therapeutics Limited (GB) 2007-11-14 EP disclosed
EP-1846395-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S Astex Therapeutics Limited (GB) 2007-10-24 EP disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed
WO-2006077419-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed
WO-2006077419-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194562-A1 Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's CDK1, CDK3, CDK2 ALDH1A1 3685/4885KDM4E 935/4885HSD17B10 2462/4885
US-20080306069-A1 Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S GSK3A, CDK11A, CDK1 ALDH1A1 1576/4885KDM4E 1457/4885HSD17B10 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.